Revolution Medicines, Inc. 4

Anthony Mancini exercised 9,363 stock options and sold 15,448 shares of Revolution Medicines, Inc. common stock on September 10, 2026 under a 10b5-1 plan.

On September 10, 2026, Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc., exercised 9,363 stock options at $33.62 per share, acquiring 9,363 shares of common stock, and on the same day sold an aggregate 15,448 shares of common stock in a series of open-market transactions at weighted average prices between approximately $203.28 and $207.17 per share pursuant to a Rule 10b5-1 trading plan, resulting in direct ownership of 43,890 shares of common stock (including 43,700 restricted stock units) and an additional 9,363 options remaining exercisable until March 31, 2035.

Filing Facts

CIK

1628171

Ticker

RVMD

Form

4

Source Type

fda

Accession

0002124509-26-000004

Alert Tier

6